Format

Send to

Choose Destination
Diabetes Metab Res Rev. 2009 May;25(4):321-4. doi: 10.1002/dmrr.960.

The anti-interleukin-1 in type 1 diabetes action trial--background and rationale.

Author information

1
Steno Diabetes Center and Hagedorn Research Institute, DK-2820 Gentofte, Denmark.

Erratum in

  • Diabetes Metab Res Rev. 2009 Nov;25(8):780.

Abstract

Type 1 diabetes (T1D) is caused by an inflammatory destruction of pancreatic beta-cells. Pro-inflammatory cytokines, in particular interleukin-1 (IL-1), have been suggested to be effector molecules based on the observations that pro-inflammatory cytokines cause beta-cell apoptosis in vitro and aggravate diabetes in vivo, and that inhibition of the action of these cytokines reduce diabetes incidence in animal models of type 1 diabetes and islet graft destruction. This review presents the rationale for and design of a recently launched double-blind, multicenter, randomized clinical trial that investigates the effect of interleukin-1 antagonism on beta-cell function in subjects with T1D of recent-onset.

PMID:
19405081
DOI:
10.1002/dmrr.960
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center